Genmab A/S Sponsored ADR (GMAB) vs Jazz Pharmaceuticals PLC (JAZZ)

Genmab A/S Sponsored ADR and Jazz Pharmaceuticals PLC are both Biotechnology companies. Genmab A/S Sponsored ADR is the larger, with a market value of $20.8B against $15.3B — 1.4× the size. Jazz Pharmaceuticals PLC trades at the lower P/E: 15.6× against 27.8×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against 12.6%. Jazz Pharmaceuticals PLC has the higher net margin (20.5% vs 19.1%) and the higher return on invested capital (8.06% vs 6.99%). Across the 21 metrics below, Jazz Pharmaceuticals PLC leads on 12 and Genmab A/S Sponsored ADR on 9.

Valuation

Metric GMAB JAZZ Biotechnology median
P/E 27.81 15.60 7.88
P/S 5.24 3.27 11.47
P/B 3.64 3.13 2.52
Price to free cash flow n/m 10.62 21.16
EV/EBITDA 21.69 10.64 0.74
EV/Sales 6.12 3.74 10.73
Earnings yield 3.60% 6.41% (28.84%)
Free cash flow yield (29.30%) 9.42% (23.03%)

Profitability

Metric GMAB JAZZ Biotechnology median
Gross margin 93.03% 88.42% 65.16%
Operating margin 25.95% 19.49% 0.00%
Net margin 19.08% 20.45% 0.00%
Free cash flow margin (153.64%) 30.79% 0.00%
Return on equity 14.00% 22.11% (57.72%)
Return on assets 8.30% 8.54% (49.22%)
Return on invested capital 6.99% 8.06% 0.00%

Growth

Metric GMAB JAZZ Biotechnology median
Revenue growth (TTM) 22.26% 12.59% 5.64%
EPS growth (last fiscal year) (12.50%) (167.51%) —
Revenue growth, 5-year CAGR 19.15% 12.54% 8.40%
Net income growth, 5-year CAGR 5.73% 0.00% 0.00%

Health

Metric GMAB JAZZ Biotechnology median
Debt to equity 0.86 0.91 0.00
Current ratio 2.46 1.78 4.73
Net debt to EBITDA 3.13 10.96 0.96

Dividend

Metric GMAB JAZZ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GMAB JAZZ Biotechnology median
Market cap 20.81b 15.34b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack